Plus Therapeutics Inc Stock News

REYOBIQ produced a clinical benefit rate of over 75% in 3 clinically relevant outcome measures RNA sequencing and circulating tumor cell reduction consistent with tumor cell death No dose limiting toxicities were observed with an overall favorable safety profile HOUSTON, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical com...

HOUSTON, Aug. 15, 2025 (GLOBE NEWSWIRE) --  Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced it reported stockholders' equity of $3 million and therefore satisfied Nasdaq Listing Rule 5550(b)(1) (the “Equity ...

Announced CNSide® CSF assay platform launch timeline Initiated the REYOBIQ dose optimization trial for patients with leptomeningeal metastases HOUSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS...

CNSide® can quantify leptomeningeal metastases (LM) over time and monitor changes in the expression of multiple targetable mutations

CNSide available for the state of Texas in August 2025 Initial commercial focus on NCI-Designated Cancer Centers and large private healthcare systems Company will expand testing services and broaden regional availability over the next 12 months HOUSTON, July 31, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing ta...

Payment is part of $17.6 million award granted for leptomeningeal cancer targeted radiotherapeutic development program Payment is part of $17.6 million award granted for leptomeningeal cancer targeted radiotherapeutic development program

Presentation by trial principal investigator at the 2025 SNO/ASCO CNS Metastases Conference Plus will also host an educational symposium with leading experts titled, “Reimagining Your Approach to Leptomeningeal Metastases” HOUSTON, July 15, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeuti...

The Joint Society for Neuro-Oncology (SNO) and the American Society of Clinical Oncology (ASCO) focus on the rapidly evolving area of central nervous system metastases